Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020

Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections

See the original post:
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020

Related Posts